Sweden · Delayed Price · Currency is SEK Getinge AB Earnings Call Transcripts
Fiscal Year 2026
-
Organic net sales grew 0.8% year-over-year, with strong order intake and solid cash flow despite SEK 226 million in tariff and currency headwinds. Life Science and Surgical Workflows led growth, while guidance for 2026 organic net sales growth of 3%-5% was reiterated.
Fiscal Year 2025
-
Record organic sales growth in Q4 2025 was driven by strong performance in Acute Care Therapies and Surgical Workflows, while Life Science lagged. Margin expansion remains a focus for 2026 despite ongoing tariff and FX headwinds, with 3%-5% organic net sales growth guided.
-
Strong organic growth and margin improvement in Q3 2025, with robust performance in Acute Care Therapies and Life Science. Tariffs and FX remain headwinds, but guidance for 2–5% organic net sales growth and long-term EPS targets are maintained.
-
Solid organic growth and margin improvement achieved despite significant tariff and FX headwinds, with strong performance in Acute Care Therapies and Surgical Workflows. Financial position remains robust, and 2025 guidance for 2–5% organic net sales growth is reaffirmed.
-
Order intake rose 7.1% and net sales grew 10.7% year-over-year, led by acute care therapies and Americas. Margins improved despite FX headwinds, and leverage remains stable post-acquisition. 2025 outlook is for 2–5% organic sales growth, with ongoing market and tariff uncertainties.
Fiscal Year 2024
-
Q4 delivered strong organic growth in orders and sales, with significant margin improvement and robust free cash flow. The phase-out of Surgical Perfusion and Paragonix acquisition were key events, while quality costs peaked but are expected to decline.
-
Order intake grew 10% year-over-year, with solid performance in most segments and regions. Margins declined due to mix, inflation, and quality costs, but financial position remains strong. Guidance for 2024 is reiterated, with organic growth of 2-5% and acquisitions adding 3-5%.
-
Net sales and order intake grew strongly in Q2 2024, with significant margin improvements and robust contributions from recent acquisitions. Quality-related costs are expected to normalize in H2, and guidance for organic growth and EPS remains unchanged.